BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11249572)

  • 1. TNF inhibitors in the treatment of arthritis.
    Lorenz HM
    Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
    Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
    Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Jones RE; Moreland LW
    Bull Rheum Dis; 1999; 48(3):1-4. PubMed ID: 10408141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
    Matsuno H; Yoshida K; Ochiai A; Okamoto M
    J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumor necrosis factor antagonism in clinical practice.
    Keystone EC
    J Rheumatol Suppl; 1999 May; 57():22-8. PubMed ID: 10328139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
    Haraoui B
    J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Daily practice using the guidelines for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis].
    Soen S
    Clin Calcium; 2008 Aug; 18(8):1169-75. PubMed ID: 18677056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.